Anti-Xa activity of enoxaparin and nadroparin in patients with acute coronary syndrome

Clinical studies have clearly revealed that low-molecular-weight heparins (LMWHs) are an effective alternative to unfractionated heparin in the therapy of acute coronary syndrome (ACS); however, data on the comparison of different LMWHs are sparse. To compare the inhibition of coagulation factor Xa...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and clinical cardiology 2008, Vol.13 (4), p.175-178
Main Authors: Ostadal, Petr, Alan, David, Vejvoda, Jiri, Segethova, Jitka, Kruger, Andreas
Format: Article
Language:English
Subjects:
Clinical Cardiology: Original
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical studies have clearly revealed that low-molecular-weight heparins (LMWHs) are an effective alternative to unfractionated heparin in the therapy of acute coronary syndrome (ACS); however, data on the comparison of different LMWHs are sparse. To compare the inhibition of coagulation factor Xa by enoxaparin and nadroparin in the therapy of ACS. Thirty-eight consecutive patients with ACS were randomly assigned to enoxaparin (group E, n=18) or nadroparin (group N, n=20) in the recommended dose. Anti-Xa activity was measured 3 h after administering the first dose of LMWH. Baseline demographics (age, sex) and clinical (type of ACS, pain-to-door time, elevation of troponin, percutaneous coronary intervention performed, smoking status, and history of diabetes, hypertension and hyperlipoproteinemia) characteristics were similar in both groups. Anti-Xa activity was significantly higher in group E than in group N (0.65+/-0.05 U/mL versus 0.30+/-0.03 U/mL; P
ISSN:1205-6626